Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155

NCT00818480 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00818480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00818480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
August 31, 2012
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non-hodgkin's lymphoma, prostate cancer